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AbsTrACT
background and objective Familial Mediterranean 
fever (FMF) is the most common monogenic 
autoinflammatory disease (aiD) worldwide. The disease 
is caused by mutations in the MEFV gene encoding the 
inflammasome sensor Pyrin. clinical diagnosis of FMF is 
complicated by overlap in symptoms with other diseases, 
and interpretation of genetic testing is confounded by 
the lack of a clear genotype–phenotype association for 
most of the 340 reported MEFV variants. in this study, 
the authors designed a functional assay and evaluated 
its potential in supporting FMF diagnosis.
Methods Peripheral blood mononuclear cells (PBMcs) 
were obtained from patients with Pyrin- associated 
autoinflammation with an FMF phenotype (n=43) or 
with autoinflammatory features not compatible with 
FMF (n=8), 10 asymptomatic carriers and 48 healthy 
donors. sera were obtained from patients with distinct 
aiDs (n=10), and whole blood from a subset of patients 
and controls. The clinical, demographic, molecular 
genetic factors and other characteristics of the patient 
population were assessed for their impact on the 
diagnostic test read- out. interleukin (il)-1β and il-18 
levels were measured by luminex assay.
results The ex vivo colchicine assay may be performed 
on whole blood or PBMc. The functional assay robustly 
segregated patients with FMF from healthy controls and 
patients with related clinical disorders. The diagnostic 
test distinguished patients with classical FMF mutations 
(M694V, M694i, M680i, r761H) from patients with other 
MEFV mutations and variants (K695r, P369s, r202Q, 
e148Q) that are considered benign or of uncertain 
clinical significance.
Conclusion The ex vivo colchicine assay may support 
diagnosis of FMF and functional subtyping of Pyrin- 
associated autoinflammation.
InTroduCTIon
Monogenic autoinflammatory diseases (AIDs) are a 
rapidly expanding group of genetically diverse but 
phenotypically overlapping inflammatory disorders 
caused by primary dysfunction of the innate immune 
system.1–3 They are also referred to as ‘periodic fever 
syndromes’ because many of these diseases feature 
recurrent fevers and episodes of systemic or organ- 
specific inflammation. They can cause significant 
morbidity and even mortality. A clinical challenge is 
that efficient diagnosis is hampered by overlapping 
clinical features and non- specific symptoms that 
are shared by patients suffering from diseases with 
distinct aetiologies. Moreover, patients suffering 
from AIDs with similar underlying mechanisms, 
who respond to particular therapies, may present 
with atypical or even distinctive symptoms.4 While 
genetic testing is widely implemented for AID 
diagnosis, interpretation of genetic results is often 
challenging, which has even become more complex 
with the availability of next- generation sequencing 
allowing multiple genes to be tested simultaneously 
and generating an increasing number of variants, 
frequently of unknown significance.5 6 Thus, there 
clearly is a growing need for new or improved tools 
to diagnose these diseases.
Key messages
What is already known about this subject?
 ► Familial Mediterranean fever (FMF) is the most 
common monogenic autoinflammatory disease 
(AID), affecting an estimated 150 000 patients.
 ► More than 340 disease- associated variants 
in MEFV, the causal gene in FMF, have been 
reported.
 ► FMF diagnosis is primarily clinical, and further 
supported by review of ethnic origin, family 
history and genetic information.
 ► Diagnosis delay is common in FMF, and 
complicated by incomplete clinical presentation 
and overlap in symptoms with other periodic 
fever syndromes.
What does this study add?
 ► The study reports and validates a functional 
diagnostic test that discriminates FMF over 
healthy controls and related AIDs.
 ► The ex vivo colchicine test identifies two 
mechanistic subtypes of Pyrin- associated AID.
How might this impact on clinical practice or 
future developments?
 ► The test may help to expedite FMF diagnosis 
and timely initiation of colchicine therapy.
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With an estimated 150 000 patients, FMF is considered the 
most common monogenic AID worldwide, mainly affecting 
populations originating from the Mediterranean basin.7 Since 
its suggested use in 1972, the microtubule polymerisation inhib-
itor colchicine has become the gold standard for treatment in 
FMF, with an overall non- responder rate of only 5%–10%.8 9 
For patients who are resistant or intolerant to colchicine, anti- 
IL-1 therapy is a safe and effective alternative.10–13 Colchicine 
prevents not only FMF attacks but also disease- associated 
complications such as amyloid A amyloidosis, a severe manifes-
tation with poor prognosis.9 However, it is crucial to establish a 
timely and correct diagnosis of FMF before committing to daily, 
lifelong treatment. Current FMF diagnosis is primarily clinical, 
and further supported by review of ethnic origin, family history 
and genetic information.7 Robust and timely clinical diagnosis 
of FMF is complicated by significant overlap in symptoms and 
the clinical presentation of other AIDs, most of which do not 
respond to colchicine therapy. Additionally, interpretation of 
genetic testing may prove challenging with around 340 disease- 
associated variants in MEFV, the gene mutated in FMF patients, 
being reported in the Infevers database to date.14–16 Many of 
these variants are common in the general public, but there are 
also a number of rare variants of unknown pathogenicity. While 
in silico tools can be useful in predicting pathogenicity, care 
should be taken when used for clinical interpretation. Some 
of the most common MEFV mutations (M694V, M694I and 
M680I) are predicted as benign/non- deleterious by two such 
programmes, PolyPhen and SIFT, while having the most severe 
clinical consequences.17 18 In silico prediction for MEFV variants 
may be hampered by the fact that amino acids that cause human 
disease are often present as a wild- type allele in primates,19 but 
also by the incomplete understanding of the pathophysiological 
mechanisms underlying FMF. Acknowledging that the difficul-
ties in linking genotype and phenotype in FMF are caused by 
an incomplete understanding of the molecular pathogenic mech-
anism underlying FMF, a recently reported consensus- driven 
pathogenicity classification was able to classify most variants in 
three genes causing other AID (MVK, NLRP3 and TNFRSF1A), 
but almost half of the MEFV variants (42.4%) could not be clas-
sified or were classified as ‘variants of uncertain significance’.5
MEFV was identified as the causal gene of FMF in 1997.14 15 
More recently, it was established that Pyrin, the protein encoded 
by MEFV, senses inactivation of RhoA GTPase, resulting in 
formation of an inflammasome that activates the protease 
caspase-1 and drives production of interleukin (IL)-1β and 
IL-18.20–28 In a prior study, we reported that in contrast to 
wild- type Pyrin, which requires microtubules to activate the 
inflammasome pathway, FMF- associated Pyrin mutants engage 
the inflammasome pathway independently of microtubules.24 
Here, we report that microtubule- independent activation of the 
Pyrin inflammasome in the ex vivo colchicine assay is specific 
to FMF alleles, allowing discrimination from healthy individ-
uals and patients suffering from Pyrin- associated AIDs that are 
distinct from FMF and other AIDs, including pyogenic arthritis, 
pyoderma gangrenosum, and acne (PAPA) and mevalonate 
kinase deficiency (MKD) that also have been associated with 
altered Pyrin inflammasome activation. Technical optimisation 
showed that the ex vivo colchicine assay may be performed using 
a small volume of human whole blood to support convenient 
and straightforward diagnosis of FMF. Finally, we provide an 
extensive validation of the ex vivo colchicine assay in a distinct 
population of patients suffering from FMF (n=43) and Pyrin- 
associated AID that is distinct from FMF (n=8). We show that 
the functional assay correlates with the MEFV genotype, and 
that the diagnosis of FMF almost perfectly coincides with the 
recently published consensus pathogenicity classification with 
some notable exceptions. This test thus aids in and provides 




Peripheral venous blood specimens were collected from healthy 
individuals as well as from patients with FMF using EDTA- 
coated Vacutainer tubes. Whole blood was used either fresh or 
after overnight storage at room temperature in the dark. Whole 
blood was seeded, 200 μL per 96- well, and maintained in a 5% 
CO2 incubator at 37°C.
Human PbMC isolation
Peripheral venous blood specimens were collected from healthy 
individuals as well as from patients suffering from FMF, PAPA 
or MKD. Human PBMCs were isolated from blood collected 
in EDTA- coated Vacutainer tubes followed by Ficoll- Hypaque 
density gradient centrifugation. After isolation, PBMCs were 
stored in liquid nitrogen for later usage. On thawing, PBMCs 
were allowed to recover for 1 hour at 37°C in culture medium 
consisting of Roswell Park Memorial Institute (RPMI) medium 
supplemented with 10% fetal bovine serum (FBS). Following 
cell viability determination, cells were seeded at a density of 
2.5×105 per 96- well and maintained in a 5% CO2 incubator at 
37°C.
reagents and stimulation
Activation of the Pyrin inflammasome was performed by stim-
ulating PBMCs or whole blood with Clostridium difficile toxin 
A (TcdA; 1 µg/mL; Enzo Life Sciences) alone, or with a combi-
nation of colchicine (1 µM; Sigma) and TcdA (1 µg/mL; Enzo 
Life Sciences). PBMC samples were incubated for 5 hours, while 
whole blood tests were incubated for 24 hours.
Cytokine analysis
Human IL-1β and IL-18 cytokine levels were determined in cell 
culture supernatants by magnetic bead- based multiplex assay 
using Luminex technology (Bio- Rad). The IL-1β and IL-18 ratios 
were calculated by dividing the cytokine level of the combined 
colchicine TcdA treatment by the cytokine level of the treatment 
with TcdA alone. GraphPad Prism V.6.0 software was used for 
data analysis.
statistics
To evaluate the predictive accuracy of the functional assay, a 
receiver operating characteristic (ROC) curve was generated 
using GraphPad Prism V.7.01 software. The area under curve 
(AUC), sensitivity and specificity were calculated with the latter 
two being used to determine the Youden index. For the anal-
ysis of variance, a linear model of the form y=µ+MEFV geno-
type+gender+origin+age+error was fitted to the IL-1β ratio 
and IL-18 ratio data of the patients. The term MEFV genotype 
was constructed as a factor product of all 15 genotype vari-
ants having wild type, homozygous and heterozygous as levels. 
Significances of the MEFV genotype, gender, origin and age 
effects were assessed by an F test. A 2×2 table summarising the 
outcome of the assay and the presence or absence of a particular 
clinical parameter was generated, followed by a Fisher’s exact 
test to assess potential correlations of the clinical parameters of 
the patient cohort presented in online supplementary table 1 and 
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the ex vivo colchicine assay. To examine the potential correla-
tion between the assay and the clinical response to colchicine, a 
regression analysis was performed, followed by a Fisher’s unpro-
tected least significant difference (LSD) test at the 5% signif-
icance level. For all tests, p<0.05 was considered statistically 
significant.
ethical approval information
All patients and controls provided written informed consent 
for participation in the study, in accordance with ICH/GCP 
guidelines. Treating physicians provided information regarding 
the MEFV genotype, symptoms, treatment, age and gender for 
patients with FMF (see online supplementary table 1). Patients 
or the public were not involved in the design, or conduct, or 
reporting or dissemination plans of our research.
resulTs
A colchicine challenge assay to support diagnosis of FMF
We previously described the biochemical principle of a func-
tional assay that may support diagnosis of FMF.24 The Pyrin 
inflammasome pathway is activated by toxin A from Clos-
tridium difficile, resulting in the release of significant amounts 
of proinflammatory cytokines IL-1β and IL-18 from intoxicated 
monocytes and macrophages. The microtubule polymerisation 
inhibitor colchicine prohibits Pyrin inflammasome activation in 
cells expressing wild- type Pyrin. Contrastingly, cells harbouring 
the common and clinically severe FMF allele MEFVM694V 
engaged the Pyrin inflammasome and secreted IL-1β and IL-18 
in the presence of colchicine despite inhibition of microtubule 
dynamics.24 We hypothesised that determining the ratio of the 
released cytokines in the presence versus absence of colchicine 
may provide a robust and fast functional read- out to support 
functional stratification and diagnosis of FMF.24
We performed a validation study in order to assess whether 
this functional test may indeed support sensitive stratifica-
tion of a wider spectrum of patients with FMF differentiated 
according to genetic makeup, age, sex and geographical loca-
tion. Additionally, we set out to compare its selectivity against 
healthy individuals and across a spectrum of related AID. The 
study group consisted of 43 patients with FMF and 8 patients 
with Pyrin- associated AID that was not compatible with FMF. 
Patients were enrolled in four hospitals located in Italy (Bari—
21; Rome—8) and Belgium (Antwerp—7; Ghent—15). The 
median age was 20 years (2–86), and 63% patients were male. 
Along with the MEFV genotype, clinical and therapeutic char-
acteristics of the patient group are described in online supple-
mentary table 1. The control group consisted of 48 donors who 
were enrolled in three different locations (Bari—9; Rome—7; 
Ghent—32). Part of the blood donations for the control group 
were through the Red Cross, who did not pass on information 
regarding age and sex. Microtubule dependency was first tested 
for the control and FMF patient groups with both IL-1β and 
IL-18 ratios being used as a read- out (figure 1A). As expected,24 
patients with FMF and healthy controls secreted IL-1β and 
IL-18 equally in response to Clostridium difficile toxin A (TcdA) 
alone, but contrary to patients with FMF, the cytokine ratios 
for healthy donors were low because of inhibition of wild- type 
Pyrin by colchicine (figure 1A). To evaluate the effectiveness and 
accuracy of the functional test, the receiver operating charac-
teristic (ROC) curve was generated for both parameters and the 
area under curve (AUC) was calculated (figure 1B).29 30 With an 
AUC of 0.93 and 0.96, respectively, both parameters performed 
well in discriminating FMF from control samples. The Youden 
index was determined to establish the most appropriate cut- 
off value to differentiate the diseased from the non- diseased 
(figure 1C).29 This analysis resulted in respective cut- off values 
of 0.64 and 0.37 for the IL-1β and IL-18 ratio, maximising 
the specificity while maintaining a sensitivity at 0.86 for both 
read- outs. Inclusion in the cohort analysis of the eight patients 
with the prevalent MEFV R202Q, E148Q and P369S variants 
that presented with autoinflammatory features not compatible 
with FMF resulted in an AUC of 0.88 for both the IL-1β and 
IL-18 ratios, and a somewhat lower sensitivity of 0.77 for the 
assay (see online supplementary figure S1). In conclusion, these 
results suggest that the ex vivo colchicine assay can be deployed 
to discriminate patients with FMF from other Pyrin- associated 
AIDs and a control population.
ex vivo colchicine assay discriminates two mechanistic 
subtypes of FMF that correlate with pathogenicity of MEFV 
variants
The statistical parameters of the ROC curve demonstrate that 
the ex vivo colchicine assay may support the reliable iden-
tification of patients with FMF. Consistent with our previous 
findings,24 colchicine enhanced TcdA- induced IL-1β secretion 
in PBMCs of most patients with FMF as reflected by IL-1ß 
ratios>1 (figure 2A). Interestingly, early studies31–33 similarly 
reported that colchicine upregulated IL-1ß secretion and pro- 
IL-1ß transcript levels in lipopolysaccharide (LPS)- stimulated 
PBMCs, while downregulating tumour necrosis factor (TNF)-α 
and IL-6 levels. Further work is needed to understand the molec-
ular mechanisms by which colchicine modulates inflammatory 
cytokine secretion. We next performed an analysis of variance 
in order to explore the epidemiological and clinical factors 
that correlate with the measured IL-1β and IL-18 responses in 
the patient group (figure 2A,B). This analysis showed that the 
most important contributor to the variation in the IL-1β and 
IL-18 ratios among patients with Pyrin- associated AID is the 
MEFV genotype, while age has a minor, but statistically signif-
icant effect. The effects of gender and the location where the 
samples were collected were not significant (figure 2B). The clin-
ical parameters presented in online supplementary table 1, but 
amyloidosis (that did not occur in the patient cohort) were also 
assessed for potential correlations with the ex vivo colchicine 
assay by using a Fisher’s exact test. This analysis showed a lack 
of correlation with chest pain, abdominal pain and arthritis, with 
p values for these three parameters corresponding to p=0.346, 
p=0.467 and p=0.366, respectively. However, fever was signifi-
cantly correlated with the ex vivo colchicine test (p=0.017). 
Notably, a regression analysis followed by a Fisher’s unpro-
tected least significant difference test also showed a significant 
correlation between the ex vivo colchicine assay and the clin-
ical response to colchicine (figure 2B). A possible explanation 
for this correlation is that the ex vivo colchicine assay primarily 
selects for patients with classical FMF mutations, the majority of 
whom shows a favourable clinical response to colchicine therapy 
(see online supplementary table 1).
Given the key role of the MEFV genotype, IL-1β and IL-18 
ratios of patients and controls were clustered and plotted 
according to the MEFV genotype (figure 2C). Notably, this anal-
ysis showed that patients with disease- penetrant MEFV mutations 
(M694V, M694I, M680I, E148Q/R761H) are clearly separated 
from controls, whereas the functional response of patients with 
other MEFV variants (K695R, P369S, R202Q, E148Q) fully 
coincided with the controls (figure 2C). The M694V mutation 
located in exon 10 is considered to be the most pathogenic 
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Figure 1 Diagnosis of familial Mediterranean fever (FMF) using a functional assay. (A) Peripheral blood mononuclear cells from healthy donors 
(n=48) and patients with FMF (n=43) were treated for 5 hours with either Clostridium difficile toxin A (TcdA) alone or with TcdA in combination with 
colchicine before culture supernatants were analysed for interleukin (IL)-1ß and IL-18, and the TcdA+colchicine over TcdA ratio for each cytokine was 
calculated. Data are combined from multiple experiments. (B) For both parameters, the receiver operating characteristic (ROC) curve was calculated, 
as well as the area under curve (AUC). (C) For both parameters, the Youden index was calculated to determine the most appropriate cut- off point, 
given the sum of sensitivity and specificity being maximum.
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Figure 2 Functional stratification of patients with Pyrin- associated autoinflammatory disease correlates with MEFV genetic variants. (A) Combined 
representation of interleukin (IL)-1β and IL-18 ratios of the ex vivo colchicine assay with peripheral blood mononuclear cells from healthy donors 
(n=48) and the patient group composed of patients with MEFV gene variants that presented with either a familial Mediterranean fever (FMF) 
phenotype (n=43) or with autoinflammatory features not compatible with FMF (n=8). Cut- off points as determined by the Youden index are indicated. 
(B) Analysis of variance for the patient group represented by the p value of the F test. Regression analysis for potential correlation between the assay 
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Figure 3 Functional stratification of familial Mediterranean fever (FMF) patients from healthy donors, pyogenic arthritis, pyoderma gangrenosum, 
and acne (PAPA), and mevalonate kinase deficiency (MKD) patients. Peripheral blood mononuclear cells from controls, patients with FMF, and patients 
with PAPA (A) or patients with MKD (B) were treated for 5 hours with either Clostridium difficile toxin A (TcdA) alone or TcdA in combination with 
colchicine before culture supernatants were analysed for interleukin (IL)-1ß and IL-18, and the TcdA+colchicine over TcdA ratio for each cytokine was 
calculated.
FMF allele causing severe disease, both in patients that are 
homozygous and compound heterozygous for M694V.34–36 The 
functional test described here thus objectively identifies these 
patients as patients with FMF, in agreement with the consensus 
classification (see online supplementary table 2). Patients with 
the M694V mutation were enrolled at three different locations 
(Rome, Ghent and Antwerp), all of them responding with a 
clear induction of Pyrin inflammasome activity in the presence 
of colchicine in the ex vivo colchicine test. The outcome of the 
test is thus independent of the location where the sample was 
collected. The M694I and M680I alleles also map to exon 10 
and are associated with a more severe phenotype.35 Patients 
expressing these disease alleles also were clearly separated 
from the controls in the ex vivo colchicine assay (figure 2C), 
demonstrating that ex vivo colchicine testing allows identifica-
tion of FMF patients with classical MEFV mutations. Likewise, 
the functional assay confirmed the pathogenic classification of 
variant R761H (or E148Q/R761H). Interestingly, the K695R 
variant—positioned adjacent to M694V in exon 10—did not 
cluster with the classical exon 10 FMF alleles in the functional 
ex vivo colchicine assay, suggesting that the functional effect 
of this mutation on the Pyrin inflammasome differs from the 
other tested disease- associated exon 10 mutations. In addition to 
K695R, the exons 2 and 3 MEFV variants in our cohort that are 
considered benign (R202Q) or of uncertain clinical significance 
(P369S and E148Q) clustered with the control population in the 
functional ex vivo colchicine assay (figure 2C and online supple-
mentary table 2). All but one compound heterozygote patient in 
our cohort harboured at least one of the classical penetrant exon 
10 FMF alleles (M680I, M694V, M694I or R761H), and were 
objectively reported as FMF by the ex vivo colchicine assay. The 
single compound heterozygous patient in our cohort that was 
diagnosed with variants of only uncertain clinical significance 
clustered with the control population in the functional assay. 
We also analysed PBMC from a cohort of family members of 
patients (n=10) to examine whether the ex vivo colchicine assay 
is able to identify asymptomatic carriers of FMF alleles. All nine 
tested carriers of penetrant exon 10 disease mutations (eight 
heterozygous carriers for M694V and one for M694I) clustered 
together with FMF patients, whereas the carrier of prevalent 
MEFV variant E148Q clustered with the healthy donor control 
group that lacks MEFV mutations (see online supplementary file 
2). Together, these results highlight the clear correlation between 
the results of the ex vivo colchicine assay and the consensus 
pathogenicity classification of MEFV gene variants.
ex vivo colchicine assay distinguishes FMF from both healthy 
and diseased controls
We previously demonstrated that patients afflicted with 
cryopyrin- associated periodic syndrome and juvenile idiopathic 
arthritis were classified separately from patients with FMF by 
the ex vivo colchicine assay.24 To further assess specificity of the 
assay, we evaluated the response of patient groups suffering from 
AIDs of which the pathophysiological mechanisms have been 
linked to deregulated activation of the Pyrin inflammasome. 
A first group of patients was diagnosed with PAPA syndrome, 
a dominantly inherited autoinflammatory disorder caused 
by mutations in the CD2- binding protein 1 (CD2BP1) that is 
predominantly mediated by granulocytes.37 CD2BP1 and its 
murine orthologue, proline- serine- threonine phosphatase inter-
acting protein (PSTPIP1), are adaptor proteins that interact with 
several proteins involved in cytoskeletal organisation and inflam-
matory processes, including Pyrin. The mutations in PSTPIP1 
underlying PAPA syndrome trigger hyperphosphorylation and 
markedly increased binding to Pyrin.38 Consistent with the ex 
vivo colchicine assay being highly specific to FMF, results from 
the test showed that PAPA patients clustered separately from 
patients with FMF, thus confirming that the ex vivo colchicine 
assay supports reliable discrimination of patients with PAPA and 
FMF (figure 3A and online supplementary table 3A). Encouraged 
by these findings, we next examined the response of patients 
suffering from mevalonate kinase deficiency (MKD)/hyper-
immunoglobulin D syndrome (HIDS), another inflammatory 
disease that has been suggested to be associated with defective 
geranylgeranylation of RhoA GTPase and Pyrin inflammasome 
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Figure 4 Functional familial Mediterranean fever (FMF) screening 
in human whole blood. Fresh, undiluted whole blood from controls 
(n=8) and patients with FMF(n=7) was treated for 24 hours either with 
Clostridiumdifficiletoxin A (TcdA) alone or TcdA in combination with 
colchicine before culture supernatants were analysed for interleukin 
(IL)-1ß and IL-18, and the TcdA+colchicine over TcdA ratio for each 
cytokine was calculated. Results are combined from four independent 
experiments.
activation.20 39 40 MKD/HIDS is caused by mutations in the MVK 
gene that target mevalonate kinase activity in the cholesterol and 
isoprene biosynthesis pathways.41–43 Although the molecular 
aetiology of MKD/HIDS is still debated, it is clear that reduced 
MVK activity leads to build- up of mevalonic acid, and a shortage 
of cholesterol, vitamins and other products of the isoprenoid 
biosynthesis pathway, which cause uncontrolled release of IL-1β 
through incompletely understood mechanisms. However, we 
found that the response of patients with PAPA in the ex vivo 
colchicine assay resembled that of healthy controls, with both 
markedly segregating from a panel of patients with FMF with 
classical MEFV mutations (figure 3B and online supplementary 
table 3B). Together, these results demonstrate that the ex vivo 
colchicine assay is able to highly specifically stratify patients with 
FMF from healthy donors and patients suffering from related 
AIDs.
Functional FMF testing is feasible in human whole blood
Although a well- established sampling method in laboratory 
testing of disease- specific activity for inflammatory disorders, the 
isolation of PBMC is a labour- consuming and time- consuming 
activity that requires specialised laboratory equipment that is not 
commonly available in clinical laboratories. Moreover, PBMC 
purification requires larger amounts of blood draws compared 
with direct whole blood analysis. In order to facilitate broad 
adoption of ex vivo colchicine testing in routine screening of 
patients suspected of FMF, we explored whether our findings 
with purified PBMC could be replicated in whole blood testing. 
Indeed, ex vivo colchicine challenge of undiluted whole blood 
showed a clear segregation of both the IL-1β and IL-18 ratios for 
FMF patients with classical MEFV mutations and healthy donors 
(figure 4 and online supplementary table 4), establishing that the 
functional assay can be conveniently performed on fresh blood, 
bypassing the need for PBMC isolation. Notably, we confirmed 
that the assay also works in whole blood stored overnight, 
although this procedure came with significantly increased back-
ground levels for IL-18, which limited the sensitivity of IL-18 
ratio determination in both control and FMF samples (data 
not shown). Regardless, we demonstrated here that functional 
screening of FMF alleles based on ex vivo colchicine challenge is 
a technically robust procedure that may support FMF screening 
based on purified PBMC as well as whole blood.
dIsCussIon
A consensus- driven pathogenicity classification was recently 
proposed to support the urgent need for clear guidelines and 
uniform diagnosis of FMF across the world.5 An unforeseen 
outcome of this study was the large number of MEFV variants 
that were classified as ‘variants of uncertain significance’ or 
‘unsolved pathogenicity’, demonstrating the urgent need for 
insight in the functional impact of these MEFV variants on Pyrin 
function. A functional test might shed more light on the delete-
rious effect of specific variants and aid in a more straightforward 
diagnosis of the disease as exemplified by clinical experience in 
XIAP (X- linked inhibitor of apoptosis) deficiency.44 Here, we 
presented and validated a robust functional assay that is able to 
specifically stratify patients with FMF from healthy controls, as 
well as from patients suffering from distinct Pyrin- associated 
autoinflammation and related AIDs. We demonstrated that 
the secretion ratios of IL-1β and IL-18 can be used together to 
increase the robustness of the ex vivo colchicine assay, although 
it remains possible to rely on a single cytokine for reading out 
results. When whole blood is used for testing, we noted that 
IL-1β outperforms IL-18, especially in samples that have been 
stored overnight prior initiation of the test.
We showed that the primary variable determining the outcome 
of the ex vivo colchicine assay is the MEFV genotype. While 
we noted that age may have a minor contribution, this may 
be related to the fact that patients with the most severe FMF 
mutations are symptomatic at a younger age. Within the FMF 
patient population, M680I, M694V, M694I and V726A are the 
most common disease- associated pathogenic mutations.45–47 The 
ex vivo colchicine assay clearly classifies patients carrying the 
M694V, M680I or M694I mutations as patients with FMF, thus 
supporting the validity of the test. Unfortunately, no conclusion 
could be drawn for the V726A mutation because only patients 
harbouring this mutation in a compound heterozygous state 
participated in our study.
The consensus agreement is that the E148Q variant in exon 2 
is a highly prevalent MEFV variant of ‘uncertain clinical signif-
icance’. Results from the ex vivo colchicine assay support this 
assessment by showing that the functional response of patients 
with the E148Q variant resembles that of healthy donors 
expressing wild- type Pyrin, contrary to patients with disease- 
penetrant FMF mutations such as M694V. Moreover, colchicine 
was not beneficial in patients with E148Q variants included in 
this study, further supporting the classification of these patients 
as Pyrin- associated periodic fever that is distinct from FMF (see 
online supplementary tables S1–S2).
R202Q is another heavily debated variant. Akin to E148Q, 
R202Q is located in exon 2 and highly prevalent in control popu-
lations. The current consensus classifies this variant as benign.48 
Functional evaluation in the ex vivo colchicine assay showed that 
the R202Q Pyrin variant responded similarly to wild- type Pyrin. 
Furthermore, unlike patients with classical FMF mutations, none 
of the R202Q- bearing patients in our study benefitted from 
colchicine therapy (see online supplementary table 1).
P369S is an exon 3 variant for which limited genetic and clin-
ical data are currently available.48 The variant can be present 
by itself or as part of a complex (E148Q- P369S- R408Q)49 as is 
the case for one of the compound heterozygous patients in our 
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patient cohort. Similar to E148Q and R202Q, P369S is highly 
common (2%–3% of the overall population) and is therefore 
to be rather considered a polymorphism. In addition, the mild 
phenotype and incomplete penetrance that have been reported 
for patients with P369S variants matches with the consensus 
agreement that this variant should be classified as one of 
‘uncertain significance’.45 Notably, the ex vivo colchicine assay 
corroborates this conclusion by showing that the variant clearly 
segregated from disease- penetrant FMF mutations.
We also evaluated the R761H variant in the present study. In 
our patient population, this exon 10 variant was always present 
in combination with exon 10 mutation M694V or the exon two 
variant E148Q. Both the E148Q and R761H variants are usually 
considered low penetrance alleles, although they have been asso-
ciated with FMF in patients from a recently described novel 
endemic area in southeastern Italy.50 Interestingly, patients with 
compound heterozygous E148Q- R761H alleles responded simi-
larly to patients with disease- penetrant FMF mutations in the ex 
vivo colchicine test. Given that E148Q does not cause FMF as 
discussed above, we conclude that the R761H mutation renders 
Pyrin activation independent of microtubule dynamics, similarly 
to the disease- penetrant FMF mutations M680I, M694V and 
M694I.
The K695R allele, positioned adjacent to the most common 
pathogenic M694V mutation in exon 10, recently made the 
switch from ‘uncertain significance’ to ‘likely pathogenic’ based 
on the consensus agreement of an expert team.5 7 Our results 
from the ex vivo colchicine test, however, show that the func-
tional response of this mutation clearly differs from that of 
classical exon 10 FMF mutations, including the adjacent M694 
disease alleles, thus suggesting that Pyrin inflammasome activa-
tion in AID patients with K695R alleles may differ mechanisti-
cally from that in FMF patients with classical exon 10 mutations. 
Further research is required to understand how Pyrin inflam-
masome signalling is deregulated in patients with the K695R 
mutation.
Notably, we observed a significant correlation between the 
ex vivo colchicine assay and the clinical response to colchicine 
(p<0.05), possibly because the ex vivo colchicine assay primarily 
selects for patients with classical FMF mutations, the majority 
of whom shows a favourable clinical response to colchicine 
therapy. At first sight, this may appear paradoxical because 
identification of FMF alleles by the ex vivo colchicine assay is 
based on the inability of high colchicine concentrations (in the 
range of 0.1–1 μM) to inhibit inflammasome activation by FMF- 
associated Pyrin mutants.24 However, plasma concentrations of 
colchicine that are therapeutically effective in patients with FMF 
(<4 ng/mL or <0.01 µM)51 fail to robustly inhibit TcdA- induced 
secretion of IL-1ß and IL-18 from TcdA- stimulated PBMCs of 
healthy donors (data not shown). This suggests that colchicine 
likely exerts its therapeutic benefit in patients with FMF through 
other, yet incompletely understood mechanisms that clearly 
warrant further investigation,8 51 52 and emphasises that the 
functional response in the ex vivo colchicine assay should not 
be interpreted as a predictive marker of the clinical response to 
colchicine therapy.
Regardless, the ex vivo colchicine assay presented here 
supports straightforward functional stratification of patients 
with FMF. Moreover, the test may enable in- depth mechanistic 
studies of the many prevalent and rare MEFV variants and muta-
tions to examine whether and how they impact Pyrin function to 
promote Pyrin- associated AID.
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